Structure Therapeutics price target raised to $105 from $65 at JPMorgan

JPMorgan raised the firm’s price target on Structure Therapeutics (GPCR) to $105 from $65 and keeps an Overweight rating on the shares. The firm sees the upcoming data of the company’s oral small molecule amylin, ACCG-2671, in the second half of 2026 adding ” another leg to the story.” Structure may have a “differentiated offering” in addition to aleniglipron, which is on track to be the second oral small molecule GLP-1 to market, the analyst tells investors in a research note.